Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) ... ( MEK inhibitors may have broad utilit...)

HOME >> MEDICINE >> TECHNOLOGY

Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors

Date:4/15/2008

"MEK inhibitors may have broad utility in the treatment of human cancers and inflammatory diseases. We are pleased to have two compounds in this class, both with excellent preclinical profiles and promising human pharmacokinetics, moving forward in clinical development," said Barry D. Quart, PharmD, Ardea Biosciences' President and CEO. "We constantly strive to diminish the inherent risk of drug development by having multiple compounds, from structurally different chemical classes, moving through development and we are excited to complete Phase 1 testing of our lead MEK inhibitor, RDEA119, and progress RDEA436 into Phase 1 clinical testing, in the second half of 2008."

The posters are available on the Company website (http://www.ardeabio.com/) under the titles "RDEA119, a Potent and Highly Specific MEK Inhibitor is Efficacious in Mouse Tumor Xenograft Studies" and "RDEA436, a Novel MEK Inhibitor with Favorable Pharmacokinetic Properties."

About RDEA119 and RDEA436

RDEA119 and RDEA436, non-ATP competitive, highly-selective MEK inhibitors for the treatment of cancer and inflammatory diseases, are two of the compounds from Ardea's MEK inhibitor research and development program. RDEA119 has shown potential as a potent and selective inhibitor of MEK, which is believed to play an important role in cancer cell proliferation, apoptosis and metastasis. Preclinical and clinical results suggest that RDEA119 has favorable properties, including oral dosing, excellent selectivity and limited retention in the brain, which, in turn, may result in a reduced risk of central nervous system (CNS) side effects. Preclinical data shows that RDEA436 is a potent in vitro and in vivo inhibitor of MEK, has favorable pharmacokinetic properties with low CNS penetration and a long half-life in a human micro-dose study indicating the potential for once daily dosing in humans.

About Ardea Biosciences

Ardea
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
9. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
10. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
11. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells

Post Your Comments:

(Date:5/17/2013)... N.Y. , May 17, 2013 Lakeland Industries, ... manufacturer of protective clothing for industry, healthcare and to ... will release its financial results for the fiscal 2013 ... Tuesday, May 21, 2013 at stock market close and ... at 4:30 p.m. eastern. (Logo: http://photos.prnewswire.com/prnh/20120611/NY21959LOGO ...

(Date:5/17/2013)... 2013 Technology advances have had a profound ... a constantly evolving communication environment, companies need to ... with internal executives. It is challenging, however, to ... and tools that are part of today,s communication ... Best Practices, LLC explores the various internal communication ...

(Date:5/17/2013)... -- Sony Biotechnology Inc. ("Sony") today announced the launch of ... be exhibiting and taking orders for this system at ... San Diego Convention Center in ... - 22. The SP6800 Spectral Analyzer ... into new and novel functionalities for the immunology, oncology, ...

Breaking Medicine Technology:Lakeland Industries to Report Fiscal Fourth Quarter and Year End Financial Results and Conduct Conference Call 2 Internal Communication Strategies and Tactics that Resonate with Key Stakeholders and Drive Organizational Effectiveness 2 Sony Biotechnology Inc.'s New Technology for Science Provides Researchers Results in Color 2

[0] Lakeland Industries to Report Fiscal Fourth Quarter and Year End Financial Results and Conduct Conference Call [0] Internal Communication Strategies and Tactics that Resonate with Key Stakeholders and Drive Organizational Effectiveness [0] Sony Biotechnology Inc.'s New Technology for Science Provides Researchers Results in Color

... 13 Pacific Bridge Medical, a leading Asia medical consulting firm, ... 26, 2010 at 11am EDT . , ... Taiwan is the sixth largest pharmaceutical market in the Asia Pacific ... health care system. This webcast will give an overview of Taiwan and ...

... May 13 Omeros Corporation (Nasdaq: ... based on successful preclinical studies, the Company has selected ... has initiated the cGMP manufacturing development process in preparation ... proprietary, fully human, monoclonal MASP-2 antibodies shut down the ...

Cached Medicine Technology:Pacific Bridge Medical to Host Taiwan Drug Registration Webinar 2 Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders 2 Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders 3 Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders 4

Pacific Bridge Medical to Host Taiwan Drug Registration Webinar Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders

(Date:5/20/2013)... 20, 2013 Dr. Fanny J Berg, located ... gentle fractional laser treatment clinically proven to fight the effects ... + Brilliant are designed to prevent and address signs ... can visibly illuminate skin tone, renew and smoothen skin texture, ... reduce the appearance of pores. Developed by the manufactures of ...

(Date:5/20/2013)... By Randy Dotinga HealthDay Reporter , , SUNDAY, ... that robs sufferers of deep sleep by endlessly and ... age. Now, a small new study raises the possibility ... by -- Alzheimer,s disease. Don,t worry just ... preliminary, and it,s possible that there may be no ...

(Date:5/20/2013)... 2013 A novel service for personalized research ... company has been in the field of providing expert research ... sure that scholars are able to maintain a direct contact ... stages and has been priced at $1000. , Students who ... assigned to the project, who will handle all aspects. Scholars ...

(Date:5/20/2013)... (PRWEB) May 20, 2013 Inspired by her ... The Woodlands personal trainer , Shanna Layne came up with ... her boot camp business host a clothing drive ... camps donated 35 bags worth of clothing to Something Special, ... Loss Their Gain” campaign was a huge success. , Being ...

(Date:5/20/2013)... May 20, 2013 The report, ... Snacks, Breakfast Cereals, Baking Mixes & Flour, Meat ... & Geography — Global Trends & Forecasts To ... market with analysis and forecasting of the global ... identifies the driving and restraining factors for the ...

Breaking Medicine News(10 mins):Health News:Delaware Dermatologist Now Offers Clear + Brilliant Gentle Laser Skin Rejuvenation Treatments 2 Health News:Sleep Apnea in Seniors Tied to Alzheimer's in Study 2 Health News:Sleep Apnea in Seniors Tied to Alzheimer's in Study 3 Health News:Dissertation Clinic Prescribes Customized Remedy for Researchers 2 Health News:Spring and The Woodlands Personal Training Centers Held Successful “Our Loss Their Gain” Clothing Drive to Help Local Women’s Center 2 Health News:Spring and The Woodlands Personal Training Centers Held Successful “Our Loss Their Gain” Clothing Drive to Help Local Women’s Center 3 Health News:Gluten-Free Products Market to Reach $6,206.2 Million by 2018 at a CAGR of 10.2% - New Report by MarketsandMarkets 2 Health News:Gluten-Free Products Market to Reach $6,206.2 Million by 2018 at a CAGR of 10.2% - New Report by MarketsandMarkets 3

[0] Delaware Dermatologist Now Offers Clear + Brilliant Gentle Laser Skin Rejuvenation Treatments [0] Sleep Apnea in Seniors Tied to Alzheimer's in Study [0] Dissertation Clinic Prescribes Customized Remedy for Researchers [0] Spring and The Woodlands Personal Training Centers Held Successful “Our Loss Their Gain” Clothing Drive to Help Local Women’s Center [0] Gluten-Free Products Market to Reach $6,206.2 Million by 2018 at a CAGR of 10.2% - New Report by MarketsandMarkets

... ... among winners of the 13th annual Medical Design Excellence Award given by ... pill swallowing difficulties thanks to a specially designed spout. The product has ... that they are able to ingest prescribed medications without stress or discomfort. ...

... ... Valley of the Sun, builder Carl Mulac knew he needed fresh concept, one that ... adult community that was in harmony on many different levels. In harmony with the ... the environment,” said Mulac, CEO of Joseph Carl Homes. , ...

... ... Save Children,s Lives, Fill Key Health Care Gaps Around the World , ... Westport, Conn. (Vocus) -- To address the global shortfall of 4.3 ... women who are front-line health care workers, Save the Children says in its new State ...

... than one-third of U.S. parents surveyed had delayed or refused ... -- Almost one-third of U.S. parents surveyed delayed vaccines for ... refused to have their children immunized, possibly making them more ... that children who don,t receive recommended vaccine doses by the ...

... trend, study finds , TUESDAY, May 4 (HealthDay News) -- ... the United States having an abortion increased nearly 60 percent, ... , According to the report released May 4 by the ... , The proportion of women in the overall U.S. ...

... LA (May 4, 2010) Rates of colorectal cancer ... method, according to data being presented at Digestive Disease ... older populations as well as utilization rates of virtual ... screening guidelines. DDW is the largest international gathering ...

Oralflo Pill Swallowing Cup Wins Medical Design Excellence Award, Helps Autism Spectrum Kids and Dysphagia Sufferers Take Medications With No Problem New 55+ Active Adult Community in the Valley Sings a New Song For a Mother's Day Gift with Lasting Appeal, Invest in Women Health Workers, Says Save the Children Misinformation About Vaccine Safety Puts Kids at Risk of Illness Abortion Rates Rising Among the Poor Investigators examine colorectal cancer screening methods among diverse populations

Anti-RSV IgA Assay (ELISA)....

Anti-RSV IgG Assay (ELISA)....

Rapid Immunoassay for the detection of Respiratory Syncytial Virus....

BD Directigen RSV Test fast, easy and accurate, its truly STAT. And it will help your laboratory quickly and confidently support critical antiviral therapy recommendations....

Medicine Products:

RIDASCREEN Anti-RSV IgA Assay RIDASCREEN Anti-RSV IgG Assay ImmunoCard STAT!® RSV PLUS BD Directigen RSV Test